

# Safety Data Sheet Ready to Use Citrate Buffer for Heat-Induced Epitope Recovery, pH6.0 (CA1) (EU)

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Product name Ready to Use Citrate Buffer for Heat-Induced Epitope Recovery, pH6.0

(CA1) (EU)

Product number K082

Brand Ready to Use Citrate Buffer for Heat-Induced Epitope Recovery, pH6.0

(CA1)

1.2 Relevant identified uses of the substance or mixture and uses advised against

In Vitro Diagnostic Use

1.3 Details of the supplier of the safety data sheet

Name Diagnostic Biosystems Address 6616 Owens Drive

Pleasanton CA 94588

USA

Telephone (888) 896-3350

email customersupport@dbiosys.com

1.4 Emergency telephone number

(925) 484-3350 (9AM-6PM, Monday - Friday, Pacific Standard Time)

## **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification according to Regulation (EC) No 1272/2008 (CLP)

- Acute toxicity, dermal (chapter 3.1), Cat. 3, H311
- Acute toxicity, inhalation (chapter 3.1), Cat. 4, H332
- Acute toxicity, inhalation (chapter 3.1), Cat. 5, H333
- Acute toxicity, oral (chapter 3.1), Cat. 4, H302

For the full text corresponding to the "H"-codes displayed in this section, refer to Section 16.

### 2.2 Label elements

# **Safety Data Sheet**

## Ready to Use Citrate Buffer for Heat-Induced Epitope Recovery, pH6.0 (CA1) (EU)

## Labelling according to Regulation (EC) No 1272/2008 [CLP]

## **Hazard pictograms**



1. Exclamation mark; 2. Skull and crossbones

Signal word Danger

**Hazard statements** 

H302 Harmful if swallowed
H311 Toxic in contact with skin

H317 May cause an allergic skin reaction

H332 Harmful if inhaled

**Precautionary statements** 

P261 Avoid breathing dust/fume/gas/mist/vapors/spray.

P264 Wash hands thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.

P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell,

P302+P352 IF ON SKIN: Wash with plenty of water.

P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P312 Call a POISON CENTER/doctor if you feel unwell.

P330 Rinse mouth.

P333+P313 If skin irritation or rash occurs: Get medical advice/attention.

P361+P364 Take off immediately all contaminated clothing and wash it before reuse.

P362+P364 Take off contaminated clothing and wash it before reuse.

P405 Store locked up.

P501 Dispose of contents/container to a licensed disposal company.

# **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

### Components

1. Glycerin

Concentration 25 % (volume)

Other names / synonyms 1,2,3-Propanetriol; 1,2,3-TRIHYDROXYPROPANE; 90 TECHNICAL

GLYCERINE; GLYCERIN, ANHYDROUS; GLYCERIN, SYNTHETIC; Glycerin, U.S.P.; GLYCERINE; GLYCERITOL; Glycerol; Glycerolum;

GLYCYL ALCOHOL; SYNTHETIC GLYCERINE; TRIHYDROXYPROPANE

EC no. 200-289-5 CAS no. 56-81-5

### 2. SODIUM AZIDE

Version: SDS-0104-EU, Revision: A, Date of issue: 2022-12-02, p. 2 of 9

Concentration < 0.5 % (weight)

Other names / synonyms Sodium azide (Na(N3))

EC no. 247-852-1 CAS no. 26628-22-8 Index no. 011-004-00-7

- Acute toxicity, dermal (chapter 3.1), Cat. 1 - Acute toxicity, inhalation (chapter 3.1), Cat. 2

- Acute toxicity, oral (chapter 3.1), Cat. 2

- Specific target organ toxicity, repeated exposure (chapter 3.9), Cat. 2

- Hazardous to the aquatic environment, short-term (acute) (chapter 4.1), Cat. 1

- Hazardous to the aquatic environment, long-term (chronic) (chapter 4.1), Cat. 1

### **SECTION 4: First aid measures**

## 4.1 Description of first aid measures

General notes Consult a physician. Show this safety data sheet to the doctor in attendance.

Following inhalation If breathed in, move person into fresh air. If not breathing, give artificial

respiration.

Do NOT induce vomiting. Never give anything by mouth to an unconscious

person. Rinse mouth with water. Consult a physician.

Following skin contact Rinse with plenty of water. Get medical attention if irritation develops and

persists.

Following eye contact Rinse thoroughly with plenty of water for at least 15 minutes. Get medical

attention if symptoms occur.

Following ingestion Call a poison center or doctor if you feel unwell. If vomiting occurs naturally,

have victim lean forward to reduce the risk of aspiration. Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything

by mouth to an unconscious person.

Acute and delayed symptoms and effects: May cause gastrointestinal

irritation. Signs/symptoms may include abdominal pain, stomach upset,

nausea, vomiting and diarrhea.

Self-protection of the first aider Ensure adequate ventilation. Use personal protective equipment. For

personal protection see section 8.

### 4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

### 4.3 Indication of any immediate medical attention and special treatment needed

No data available

## **SECTION 5: Firefighting measures**

Version: SDS-0104-EU, Revision: A, Date of issue: 2022-12-02, p. 3 of 9

### 5.1 Extinguishing media

Use extinguishing media appropriate for surrounding fire.

## 5.2 Special hazards arising from the substance or mixture

----

Glycerol: Carbon oxides

----

SODIUM AZIDE: Sodium oxides

### 5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

### **Further information**

No data available.

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. For personal protection see section 8.

Ensure adequate ventilation. Use personal protective equipment. For personal protection see section 8.

Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. For personal protection see section 8.

## 6.2 Environmental precautions

Should not be released into the environment. See Section 12 for additional ecological information.

### 6.3 Methods and material for containment and cleaning up

Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in container for disposal according to local regulations (see section 13).

#### 6.4 Reference to other sections

For disposal see section 13.

# **SECTION 7: Handling and storage**

## 7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2.

## 7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

### 7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

Version: SDS-0104-EU, Revision: A, Date of issue: 2022-12-02, p. 4 of 9

## **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

CAS: 26628-22-8 (EC: 247-852-1)

Sodium azide

ACGIH: 0.29 mg/m3 (C); 0.1 ppm (C) hydrazoic acid vapor TLV® inhalation; NIOSH: 0.29 mg/m3 (C); 0.1 ppm (C) hydrazoic acid vapor REL-C inhalation

CAS: 56-81-5

Glycerin

Cal/OSHA: PNOR PEL inhalation; 10 mg/m3 PEL inhalation; 5 mg/m3 PEL inhalation; NIOSH: See Appendix D REL inhalation; OSHA: 15 mg/m3 PEL inhalation; 5 mg/m3 PEL inhalation

**CAS: Unspecified** 

Glycerin

ACGIH: 10 mg/m3 TLV® inhalation

### 8.2 Exposure controls

### Appropriate engineering controls

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

### Individual protection measures, such as personal protective equipment

## **Pictograms**







### Eve and face protection

Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

## Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

#### **Body protection**

Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place., The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

### Respiratory protection

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

## Thermal hazards

No data available

### Control banding approach

No data available.

### **Environmental exposure controls**

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

# **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state Liquid
Appearance Clear
Colour Colorless
Odour Odorless

Odour threshold No data available.

pH 6.0

No data available. Melting point/freezing point Boiling point or initial boiling point and boiling range No data available. Flash point No data available. Evaporation rate No data available. Flammability No data available. Lower and upper explosion limit/flammability limit No data available. Vapor pressure No data available. Relative vapor density No data available. Density and/or relative density No data available. Solubility No data available. Partition coefficient n-octanol/water (log value) No data available. Auto-ignition temperature No data available. Decomposition temperature No data available. Kinematic viscosity No data available.

No data available.

No data available.

#### Particle characteristics

No data available.

Explosive properties

Oxidizing properties

#### 9.2 Other information

### 9.2.1 Information with regard to physical hazard classes

No data available.

### 9.2.2 Other safety characteristics

No data available.

# **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

None under normal use conditions.

### 10.2 Chemical stability

Stable under recommended storage conditions.

### 10.3 Possibility of hazardous reactions

None under normal use conditions.

#### 10.4 Conditions to avoid

Exposure to moisture.

Avoid storing in direct sunlight and avoid extremes of temperature.

Heat, flames and sparks.

## 10.5 Incompatible materials

----

Glycerol: Strong bases, Strong oxidizing agents

### 10.6 Hazardous decomposition products

Other decomposition products - No data available In the event of fire: see section 5

## **SECTION 11: Toxicological information**

## 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

## **Acute toxicity**

The ATE (dermal) of the mixture is: 1000 mg/kg bw

The ATE (gas inhalation) of the mixture is: 20000 ppmV

The ATE (vapor inhalation) of the mixture is: 100 mg/l

The ATE (oral) of the mixture is: 1000 mg/kg bw

Glycerol

LD50 Oral - Rat - 12,600 mg/kg

Glycerol

LD50 Skin - Rabbit - > 10,000 mg/kg

Sodium azide

LD50 Oral - Rat - 27 mg/kg

Sodium azide

LD50 Skin - Rat - 20 mg/kg

Sodium azide

LC50 Inhalation - Rat - 0.054 - 0.52 mg/l - 4 hr

### Skin corrosion/irritation

Based on available data, classification data are not met

## Serious eye damage/irritation

Causes eye irritation.

## Respiratory or skin sensitization

Based on available data, classification data are not met

### Germ cell mutagenicity

Based on available data, classification data are not met

### Carcinogenicity

Version: SDS-0104-EU, Revision: A, Date of issue: 2022-12-02, p. 7 of 9

## Safety Data Sheet

## Ready to Use Citrate Buffer for Heat-Induced Epitope Recovery, pH6.0 (CA1) (EU)

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

### Reproductive toxicity

Based on available data, classification data are not met

## STOT-single exposure

No data available.

### STOT-repeated exposure

No data available.

### **Aspiration hazard**

No data available.

#### 11.2 Information on other hazards

## **Endocrine disrupting properties**

No data available.

#### Other information

No data available.

# **SECTION 12: Ecological information**

## 12.1 Toxicity

Sodium azide

LC50 - Oncorhynchus mykiss (rainbow trout) - 2.96 mg/l - 96 h

Sodium azide

EC50 - Pseudokirchneriella subcapitata (green algae) - 0.348 mg/l - 96 h

## 12.2 Persistence and degradability

No data available.

### 12.3 Bioaccumulative potential

No data available.

### 12.4 Mobility in soil

No data available.

### 12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

### 12.6 Endocrine disrupting properties

No data available.

### 12.7 Other adverse effects

No data available.

Version: SDS-0104-EU, Revision: A, Date of issue: 2022-12-02, p. 8 of 9

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

#### Product disposal

Offer surplus and non-recyclable solutions to a licensed disposal company.

### Packaging disposal

Dispose of as unused product.

#### Waste treatment

No data available

### Sewage disposal

Do not let product enter drains

### Other disposal recommendations

Dispose of contents/ container in accordance with the local/regional/national/international regulations.

## **SECTION 14: Transport information**

14.1	UN Number	None
14.2	UN Proper Shipping Name	None
14.3	Transport hazard class(es)	None
14.4	Packing group	None
14.5	Environmental hazards	None
14.6	Special precautions for user	None
14.7	Maritime transport in bulk according to IMO instruments	None

## **SECTION 15: Regulatory information**

### 15.2 Chemical Safety Assessment

The supplier of this product has not conducted any Chemical Safety Assessment

### **SECTION 16: Other information**

### Full text of hazard statements referenced in Section 2

H302 Harmful if swallowed
H311 Toxic in contact with skin
H332 Harmful if inhaled
H333 May be harmful if inhaled

SDS-0104, Rev. B

### Further information/disclaimer

DISCLAIMER: The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigation to determine the suitability of information for their particular purposes. In no event shall Diagnostic BioSystems be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, whatsoever arising, even if Diagnostic BioSystems has been advised of the possibility of such damages.